XKRX
118000
Market cap15mUSD
Oct 08, Last price
1,199.00KRW
1D
0.00%
1Q
-4.16%
Jan 2017
-89.00%
IPO
-82.80%
Name
The MediPharm Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Headquartered in Seoul, South Korea, Wooridul Huebrain Limited was founded in 2009. The company's operations span the medical, life and health, pharmaceutical, and storage industries. Its offerings include a range of medical equipment and devices, health-related apparatus, pharmaceutical products, and computer server solutions. The firm rebranded as Wooridul Huebrain Limited in April 2014, having previously operated under the name Wooridul Life Sciences Limited.
Key people
Su Jin Lee
Chief Executive Officer, Director · since 2024
Internal Auditor · since 2024
Jin Su Jung
Internal Auditor · since 2009
Gwan Sik Choi
Director · since 2013
Director · since 2024
Director · since 2024
Su Gyeong Kim
Director · since 2012
Seung Ryeol Lee
Director · since 2011
Byeong Yil Seo
Director · since 2012
Gyu Seong Jung
Non-Executive Independent Director · since 2013
Cheol Beom Lee
Non-Executive Independent Director · since 2009
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||